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Abstract
Background: Ventilator-associated pneumonia (VAP) is considered the most common nosocomial infection in the
intensive care unit (ICU), but its features are not fully known in many hospitals in Brazil. We identified clinical and
epidemiological aspects associated with VAP in an intensive care unit (ICU) in a general public hospital in northern
Brazil and performed an analytical descriptive prospective cohort study.
Methods: We analyzed data from thirty-three patients who developed VAP while in the ICU. Clinical and
epidemiological data of patients were obtained and tracheal secretions were submitted to culture. Microbial
isolates were identified and evaluated for resistance against antimicrobial agents by using the automated Vitek 2
system.
Results: The frequency of VAP was 26.2% in patients submitted to invasive mechanical ventilation for at least
48 hours, and death occurred in 78.8% of cases. Only the presence of comorbidity showed a significant association
(P = 0.029) with death. The most commonly found bacteria were Pseudomonas aeruginosa, Acinetobacter spp., and
Enterobacteriaceae. We also found a frequency of 54.5% of multiresistant bacteria associated with VAP, and
previous antibiotic therapy was used in 97% of patients.
Conclusions: VAP in our ICU presented with a high frequency and was mainly caused by multiresistant bacteria.
Implementation of rational protocols for the use of antibacterial agents and rapid delivery of culture and
susceptibility test results are essential. This may help decrease VAP-related mortality rates by multiresistant bacteria
in the ICU.
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Background
Ventilator-associated pneumonia (VAP) is a pulmonary
infection that appears after 48 hours of endotracheal in-
tubation and when invasive mechanical ventilation
(IMV) is initially used [1]. VAP is considered the most
common nosocomial infection in the intensive care unit
(ICU), with an incidence that varies between 9% and
27% depending on the population, type of ICU, and
diagnostic criteria applied [2,3]. VAP prolongs the
hospitalization stay and need for mechanical ventilation,
which considerably increases costs [4,5]. VAP-associated
mortality rates vary between 20% and 70%, and are even
higher when caused by multiresistant pathogens or when
inadequate antibiotic therapy is used [6,7].
VAP pathogenesis may include aspiration of oropha-
ryngeal mucous, tracheal intubation, inadequate hand-
ling of airways, contaminated inhalation, hematological
dissemination of a distant infectious area, and exogenous
contamination of the pleural space [3,7]. Patients’ cha-
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racteristics and the treatment they receive may also favor
the development of VAP [6].
Bacterial resistance is an important factor associated
with increasing mortality rates in patients with VAP. The
main VAP-multiresistant bacteria are Gram-negative
organisms, such as Pseudomonas aeruginosa, Acinetobacter
baumannii, Klebsiella pneumoniae, Enterobacter spp., and
Escherichia coli. However, the incidence of methicillin-
resistant Staphylococcus aureus (MRSA) has gradually
increased [4,6,8]. Increasing detection of these bacteria in
association withVAP has been attributed to the widespread
use of antimicrobials, prolonged use of IMV in the ICU,
and the presence of comorbidity [9-11].
Determination of the VAP-associated epidemiology in
each medical institution is important for developing
effective prophylactic and therapeutic strategies aiming
to decrease the incidence of VAP-associated mortality
rates, and also to optimize the use of antimicrobial agents
[12-14]. In this study, we identified the epidemiological
aspects associated with VAP in the ICU of a public
hospital in Amapá, Brazil, during June 2009 to May 2010.
Methods
Study design and settings
This was an analytical descriptive prospective cohort
study performed in an ICU with 11 beds in a general
public hospital in Macapá, Amapá, northern Brazil. The
study was performed between June 2009 and May 2010
with patients undergoing mechanical ventilation. This is
a reference hospital for adult surgery and medical clinics.
This hospital has 50 surgical beds, 98 beds for clinics,
and 11 isolated beds, as well as the 11 beds in the ICU.
Inclusion criteria
All patients hospitalized in the ICU who developed
pneumonia after 48 hours of invasive mechanical venti-
lation were included in the study. Patients were followed
until discharge from the ICU or until death. Only the
first episode of VAP was considered for each patient.
Ethics
Informed consent and approval by the Ethics Committee
were waived because of the observational nature of the
study (Ethics Committee in Research of the Medical
School Seama in Macapá, Amapá, Brazil, number 030/09).
Data collection
The following data were collected from VAP patients:
age, sex, cause for hospitalization in the ICU (clinical
or surgical), presence of comorbidities, date of ICU
hospitalization, and date IMV was initiated. VAP was
classified as late-onset (>4 days) or early-onset (≤4 days)
[2]. Exposure to risk factors was also evaluated. These risk
factors were as follows: consciousness level according to
the Glasgow scale; transfusion of more than four units of
hemoderivates in the last 10 days; antibiotic therapy dur-
ing the 15 days prior VAP; tracheostomy and hemodialysis
for at least 48 hours; invasive procedures (probes, cathe-
ters or drains); hospitalization; IMV; and pneumonia in
the last 30 days. Empirical antibiotic therapy initiated after
VAP treatment was also evaluated for its adequacy
according to culture and susceptibility test results.
Bacterial cultures were classified as mono or poly-
microbial (>1 microorganism isolated). The time under
IMV and the duration of ICU hospitalization were also
considered.
Microbiological diagnosis and susceptibility test to
antimicrobial agents
At the time of diagnosis, tracheal secretion was collected
from patients through an aspiration sterile procedure using
a probe connected to a Transbac CW system (Probac, São
Paulo, Brazil), according to the manufacturer’s recommen-
dations. Collection was performed before the antimicrobial
agent in use was replaced by a different agent. Samples
were sent to the microbiology lab for quantitative culture
in blood agar and in MacConkey agar. After overnight
incubation under appropriate conditions, the growth was
quantified. Cultures were considered positive when growth
of at least 105 CFU/mL was observed [15]. All cultures
were submitted to bacterial identification and a susceptibi-
lity test to antimicrobial agents using the automated Vitek
2 system (bioMérieux).
Definitions
We applied the diagnostic criteria described by the CDC
(1988) to define VAP, which is based on the presence of
more than one clinical sign associated with a radiological
sign. The clinical criteria included a body temperature
of >38°C or <36°C with no other known cause, and/or
<4.000 or >12.000/mm3 leucocytes. Other criteria also
included at least one of the following signs: purulent
tracheal secretion or a change in characteristics of an
existing secretion; suggestive auscultation and culture of
tracheal secretion positive at a threshold of 105 CFU/
mL. Radiological criteria included new or progressive
pulmonary infiltrates, or consolidation or cavitation in
chest radiography [1].
Antibiotic therapy was considered adequate when
initiated no later than 48 hours after VAP diagnosis and
when it included at least one antimicrobial agent to
which the etiological agent was described as susceptible
in the antibiogram result [10]. Previous antibiotic the-
rapy was characterized by the use of antimicrobial agents
for more than 24 hours during a 15-day period before
the VAP episode [11].
Classification of multiresistant bacteria included MRSA,
extended-spectrum β-lactamase-producing enterobacte-
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ria, P. aeruginosa, and other nonfermenting organisms
(A. baumannii and Stenotrophomonas maltophilia) resist-
ant to three or more of the following classes of antibiotics:
antipseudomonal cephalosporins or penicillins, carbape-
nems, fluoroquinolones, and aminoglycosides [10].
Statistical analysis
Data were analyzed using the software Bioestat version
5.0 [16]. The Shapiro-Wilk test was used to verify the
normality of the numeric variables. The G-test of inde-
pendence was used to evaluate microbial frequency and
bacterial resistance with death. Pearson’s correlation was
used for numerical variables with normal distribution.
Abnormally distributed variables were analyzed by
Spearman’s correlation. Significance was accepted when
P < 0.05.
Results
Of 126 patients submitted to IMV for at least 48 hours,
33 (26.2%) developed VAP while in the ICU during June
2009 to May 2010. Death occurred in 26 (78.8%) cases
(data not shown). Table 1 shows the clinical and
epidemiological characteristics of these 33 patients who
developed VAP. For all variables tested, we found that
only the presence of comorbidity showed a significant
association (P = 0.029) with death (Table 1).
Table 2 shows the distribution of microorganisms
isolated after quantitative cultures, and their association
with drug multiresistance and patient death. For the 32
samples for which lab results were obtained (one sample
was missed), 22 (68.8%) showed one etiological agent
and 10 had polymicrobial culture (31.2%), in which up
to three different microorganisms were isolated. Thirty-
nine species of bacteria were detected, including
P. aeruginosa (11/39, 34.4%), Acinetobacter spp. (11/39,
34.4%), and members of the Enterobacteriaceae family
(Klebsiella, Enterobacter, and E. coli: 8/32, 25%) as the
most frequent. The difference in the species frequency
in VAP was significant (P = 0.003). Twenty-three of the
39 (59%) bacterial species were multiresistant. At least
one type of multiresistant bacteria was found in 20
(62.5 %) patients. A high frequency of multiresistance
was found in Acinetobacter spp. (81.8%), S. aureus
(80%), and P. aeruginosa (72.7%). A significant associ-
ation was found between the frequency of these micro-
organisms and death (P = 0.0001), and also between the
Table 1 Characteristics of 33 VAP patients after ICU






Categorical variables, n (%)
Gender, male 20 (76.9) 4 (57.1) 0.3122
Cause of ICU admission
Clinical 12 (46.2) 3 (42.9) 0.7859
Surgical 14 (53.8) 4 (57.1)
Comorbidities 16 (61.5) 1 (14.3) 0.0291*
Glasgow < 9 18 (69.2) 4 (57.1) 0.8808
Late-onset VAP 17 (65.4) 5 (71.4) 0.8808
Previous pneumonia 9 (34.6) 1 (14.3) 0.5552
Invasive procedures
Nasogastric probe 25 (96.1) 7 (100) 0.5177
Vesical probe 26 (100) 7 (100) 1.000
Central vascular
catheter
19 (73.1) 4 (57.1) 0.7285
Hemodialysis 6 (23.1) 1 (14.3) 0.9874
Tracheostomy 10 (38.5) 5 (71.4) 0.2590
Prior IMV 10 (38.5) 1 (14.3) 0.4385
Appropriate antibiotic
therapy
6 (23.1) 4 (57.1) 0.2147
Polymicrobial etiology 9 (34.6) 1 (14.3) 0.5552
Transfusion of
hemoderivatives ≥ 4
5 (19.2) 2 (28.6) 0.9874




Age (years) 59 (48.5 – 68.8) 33 (28 – 59) 0.2466
Hospital stay (days) 30 (12.5 – 47.3) 48 (43 – 55.5) 0.0613
Duration of IMV (days) 22 (11.3 – 44) 28 (24.5 – 30.5) 0.7916
IMV: invasive mechanical ventilation; VAP: ventilator-associated pneumonia;
CVC: central venous catheter; ICU: intensive care unit. *p < 0.05.
Table 2 Frequency of multiresistant bacteria from 32 VAP








Staphylococcus aureus 5 (15.6) 4 (80.0) 5 (100)
Gram-negative
Pseudomonas aeruginosa 11 (34.4) 8 (72.7) 8 (72.7)
Acinetobacter spp. 11 (34.4) 9 (81.8) 9 (81.8)
Klebsiella spp. 5 (15.6) 2 (20.0) 4 (80.0)
Stenotrophomonas maltophilia 2 (6.2) - 1 (50.0)
Sphingomonas paucimobilis 2 (6.2) - 1 (50.0)
Escherichia coli 1 (3.1) - 1 (100)
Enterobacter spp. 2 (6.2) - 2 (100)
P value (G test) c 0.003 0.0083
Total 39 23 31
a Spearman correlation between death and frequency of microorganisms
(ρ = 0.905, P = 0.0001).
b Spearman correlation between death and presence of multiresistance
(ρ = 0.947, P = 0.00144).
c G Test of independence is evaluating the proportion of different
microorganisms among them.
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presence of multiresistance and death (Table 2, P =
0.001). Comparison of bacterial multiresistance and
death in VAP patients with death in VAP patients
infected with susceptible bacteria did not show any asso-
ciation (P = 0.211). No difference was observed for the
ratio of multiresistant bacteria between early-onset VAP
and late-onset VAP (data not shown).
Three species of fungus were found in four tracheal
samples. Of these, two presented with Candida albicans
in association with MRSA, and one patient presented
with Candida parapsilosis in association with a multi-
resistant Klebsiella strain. One strain of Cryptococcus
laurentii was isolated as the sole pathogen in one patient
who died (data not shown).
The resistance profiles of major Gram-negative bacteria
to selected antimicrobial agents tested are shown in Table 3.
The resistance ratio varied among antibiotics (χ2: 58.4, P <
0.0001), piperacillin (63.3%), cefepime (53.3%), aztreonam
(50%), ceftazidime (50%), and ciprofloxacin (50.0%) were
associated with most of the resistance. Those Gram-
negative bacteria were less resistant against amikacin
(20.0%), tobramycin (33.3%), and piperacillin/tazobactam
(33.3%). P. aeruginosa and Acinetobacter spp. showed high
levels of resistance against carbapenems, cephalosporins,
and fluoroquinolones. The resistance ratio of S. aureus also
varied among antimicrobial agents (G = 66.19, P < 0.0001).
All isolates showed resistance to penicillin, erythromycin,
clindamycin, and tetracycline, and were susceptible to
vancomycin, quinupristin/dalfopristin, and linezolid (data
not shown). The minimum inhibitory concentration of all
S. aureus strains for vancomycin and linezolid were 1 μg/
mL and 0.5 μg/mL, respectively. Four strains (80%) were
also classified as MRSA.
Previous antibiotic therapy was used in 97% of the
patients with VAP. The antibiotics most commonly used
were cefepime (44.4%), ceftriaxone (25.9%), ciprofloxacin
(25.9%), and imipenem (22.2%). A high, positive, and
significant correlation was observed (r = 0.8622, P =
0.0272) between previous antibiotic therapy and bacter-
ial resistance displayed by Gram-negative bacteria
(Table 4).
Discussion
The frequency of VAP mainly varies according to the
diagnostic criteria applied and to the type of ICU and
population. According to the criteria applied in this
study, the frequency of VAP was of 26.2%. Other authors
have found incidences between 9% and 27%, and this
incidence increases according to the duration of mech-
anical ventilation [17].
The mortality rate found in patients undergoing VAP
in a few studies performed in Brazil varies between
32.1% and 70.9% [18-21], which agrees with a review by
Chastre and Fagon who reported rates from 24% to 76%
[6]. The present study found a higher rate of mortality
(78.8%) than previous studies, and that comorbidity was
the only variable significantly associated with mortality
in VAP patients. The presence of some underlying con-
ditions or diseases, including cardiac surgery, acute lung
injury, and immunocompromising conditions, signifi-
cantly affect prognosis in VAP patients, and consequently,
the mortality rates are high [6].
Distinct microorganisms are described as agents of
VAP, and their frequency may differ according to many
factors, including the population of patients in the ICU,
duration of hospital stay, and methods of diagnosis.
However, in many studies, Gram-negative bacteria
were involved in more than 60% of VAP cases, with
principally P. aeruginosa, Acinetobacter spp., and
Table 3 Resistance profiles of major Gram-negative bacteria from 27 VAP patients in a public hospital of northern
Brazil
Microorganism N Antibioticsa/No. of resistant strains (%)
PIP FEP ATM CAZ CIP MEM GEN IPM TZP TOB AMK
P. aeruginosa 11 5 (45.4) 6 (54.5) 4 (36.4) 6 (54.5) 5 (45.4) 5 (45.4) 4 (36.4) 5 (45.4) 4 (36.4) 4 (36.4) 2 (18.2)
Acinetobacter spp. 11 7 (63.6) 7 (63.6) 8 (72.7) 7 (63.6) 7 (63.6) 7 (63.6) 5 (45.4) 6 (54.5) 5 (45.4) 2 (18.2) 3 (27.3)
Enterobacteriaceaeb 8 7 (87.5) 3 (37.5) 3 (37.5) 2 (25.0) 3 (37.5) 1 (12,5) 4 (50.0) 1 (12,5) 1 (12,5) 4 (50.0) 1 (12,5)
Total 30 19 (63.3) 16 (53.3) 15 (50.0) 15 (50.0) 15 (50.0) 13 (43.3) 13 (43.3) 12 (40.0) 10 (33.3) 10 (33.3) 6 (20.0)
a PIP: Piperacillin; ATM: Aztreonam; FEP: Cefepime; CAZ: Ceftazidime; CIP: Ciprofloxacin; MEM: Meropenem; GEN: Gentamicin; IPM: Imipenem; TZP: Piperacillin/
Tazobactam; TOB: Tobramycin; AMK: Amikacin. b Klebsiella (5), Enterobacter (2), and Escherichia (1).
Table 4 Correlation between previous antibiotic therapy
and bacterial resistance displayed by Gram-negative
bacteria
Antibiotic Patients with previous




Cefepime 12 (44.4) 7 (58.3) 0.8622
(0.0272)
Ceftriaxone 7 (25.9) 7 (100.0)
Ciprofloxacin 7 (25.9) 5 (71.4)
Imipenem 6 (22.2) 2 (33.3)
Amikacin 2 (7.4) -
Ceftazidime 1 (3.7) 1 (100.0)
* Spearman correlation.
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Enterobacteriaceae. Among Gram-positive bacteria,
S. aureus is the predominant agent in VAP cases
[4,10,11,22]. Results from Latin American studies are
similar to ones obtained in this study [18,20,21,23,24].
S. maltophilia has also been frequently described in VAP
cases [11,13]. Similar to these previous studies, in
our study, the most frequent microorganisms were
Acinetobacter spp., P. aeruginosa, Enterobacteriaceae,
and S. aureus. Their frequencies were also significantly
associated with death. Three isolates of Candida were
detected, but they did not appear to be involved as
etiologic agents because they were isolated in association
with multiresistant bacteria, and because yeasts have
been detected from respiratory tract specimens from
patients without disease [25,26].
Microbiological investigation of VAP is of great
importance for developing appropriate antimicrobial
therapy and for standardizing empirical therapies to be
used in the future. This is because the local susceptibility
profile of bacteria commonly associated with the disease
would already be known. In this context, the culture of
tracheal aspirate has similar importance for diagnosis
compared with invasive techniques of bronchoalveolar
wash and a protected specimen brush, and it is also a
simpler and less expensive technique [27]. However,
quantitative cultures of tracheal aspirates have low speci-
ficity (48%–78%) and sensitivity (26%–65%) [8]. In our
study, the mortality rate was high, even though etio-
logical agents were identified in 97% of the cases with
quantitative culture of the tracheal aspirates, confirming
that others factors are important in the prognosis of
VAP patients, as previously described [6].
In our study we found a frequency of 59% of mul-
tiresistant bacteria associated with VAP. In another study
in which the criteria applied for classifying multiresistant
bacteria were similar to ours, the frequency of multi-
resistant bacteria was 27% [10]. Among the most
frequent multiresistant bacteria found in VAP are P.
aeruginosa, Acinetobacter spp., and S. aureus [10,12,19].
This finding was confirmed in our study.
Because we analyzed the isolation frequency of those
bacterial species that were multiresistant, a significant
correlation with death was observed. However, no asso-
ciation was evident when we compared death in patients
displaying multiresistant isolates with death in patients
with VAP caused by non-multiresistant bacteria, which
is the ideal comparison. The lack of association between
antibiotic resistance and mortality has been previously
reported in VAP patients whose agents were P. aeruginosa
and MRSA [28,29]. However, bacterial resistance was
responsible for a high mortality rate in patients undergo-
ing VAP in many reports [9,30-32]. Such lack of associ-
ation observed in the current study is probably due to the
small sample size, which is a limitation of this study.
For bacterial resistance, it is difficult to determine the
most appropriate antimicrobial therapy for VAP, and
patients also stay for long periods in hospitals and ICUs,
where use of antimicrobial agents is greatly required
[24,33]. Additionally, the likely multiresistant bacterial
etiology of VAP increases the use of large spectrum
empirical antibiotics and of combined therapies [10].
The high levels of antibiotic resistance found among
P. aeruginosa, Acinetobacter spp., and S. aureus against
major antibiotics usually administered in patients infected
with these microorganisms could have led to inadequate
antibiotic therapy and a poor outcome in our patients.
In our study, we found that previous antibiotic therapy
was used in 97% of patients with VAP. The antibiotics
most used were cefepime, vancomycin, and cefalotin.
According to the spectrum range of antimicrobial agents
for Gram-negative bacteria, carbapenems present with the
largest spectrum range of action, followed by cefepime,
piperacillin/tazobactam, quinolones, and others [13].
Depuydt et al. observed that patients who received antibi-
otics of at least two different classes showed a higher
probability of getting infected by multiresistant bacteria
[10]. Previous use of antibiotic therapy also affects the
resistance of etiological agents of VAP [11]. Occurrence of
multiresistant P. aeruginosa and MRSA has been signifi-
cantly associated with previous exposure to ceftazidime,
while Acinetobacter spp. are associated with previous
exposure to piperacillin/tazobactam [9], which are similar
findings to our study.
Conclusions
In our study, we found that VAP in our ICU presented
with high frequency and was mainly caused by multi-
resistant bacteria. High mortality rates were found to be
associated with the frequency of certain bacterial species
and with the presence of comorbidities, while the use of
previous antimicrobial agents affected the resistance of
etiological agents of VAP.
The implementation of rational protocols for the use of
empirical antibacterial agents, based on the knowledge
of local microbiological patterns, and rapid delivery of
culture and results of susceptibility assays are essential
strategies that may help in decreasing VAP-related morta-
lity rates by multiresistant bacteria in the ICU.
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